Vicks Inhaler Nasal Stick Menthol 125mg Camphor 50mg Siberian Pine Needle Oil 10mg

国: マルタ

言語: 英語

ソース: Medicines Authority

有効成分:

CAMPHOR, PINE OIL, MENTHOL

から入手可能:

WICK Pharma - Zweigniederlassung der Procter & Gamble GmbH Sulzbacher Str. 40, 65823, Schwalbach am Taunus,, Germany

ATCコード:

R01AX30

INN（国際名）:

CAMPHOR 50 mg PINE OIL 10 mg MENTHOL 125 mg

医薬品形態:

NASAL STICK

構図:

CAMPHOR 50 mg PINE OIL 10 mg MENTHOL 125 mg

処方タイプ:

OTC

治療領域:

NASAL PREPARATIONS

認証ステータス:

Authorised

承認日:

2007-03-02

情報リーフレット

Inhaler
Nasal Stick
_Menthol 125mg Camphor 50mg _
_Siberian Pine Needle Oil 10mg_
FAST RELIEF FROM STUFFY NOSES
Inhaler
Nasal Stick
_Menthol 125mg Camphor 50mg _
_Siberian Pine Needle Oil 10mg_
FAST RELIEF FROM STUFFY NOSES
Vicks Inhaler is a 0.5 ml nasal
stick for nasal use. Insert well
into nostril. Inhale deeply to
make breathing feel cool and
clear. NOT RECOMMENDED FOR
CHILDREN UNDER 6 YEARS. Do not
store above 25°C. KEEP OUT OF
THE SIGHT AND REACH OF CHILDREN.
For EXP & Lot No. see base.
PA2294/005/001
WHAT IS VICKS INHALER AND HOW DOES IT
WORK?
Vicks Inhaler is a 0.5 ml decongestant nasal
stick containing the active ingredients:
• menthol (125mg)
• camphor (50mg)
• Siberian pine needle oil (10mg)
It also contains methyl salicylate.
When you inhale these actives through your
nose, they work on the lining of your nasal
passages to ease breathing and help relieve
a stuffy nose caused by colds or allergic
reactions.
Relief of nasal congestion associated with
upper respiratory tract disorders and
allergies.
DIRECTIONS FOR USE: (adults & children 6 years
& over): Use as often as needed. Remove the
screw cap. Insert well into nostril, holding
the other nostril closed. Inhale deeply to
make breathing feel clear and cool. NOT
RECOMMENDED FOR CHILDREN UNDER 6 YEARS.
Do not store above 25°C.
DO NOT USE VICKS INHALER:
• if you are allergic to any of its ingredients
• after the expiry date
If your symptoms persist or worsen consult
your doctor or pharmacist.
Nasal discomfort may occur very rarely. If
you get any side effects, including any not
listed, talk to your doctor or pharmacist.
You can also report side effects directly via
HPRA Pharmacovigilance,
Earlsfort Terrace, IRL - Dublin 2;
Tel: [phone]; Fax: [phone];
Website: www.hpra.ie;
e-mail: [e-mail].
KEEP OUT OF THE SIGHT AND REACH OF
CHILDREN
FURTHER INFORMATION
All enquiries to licence holder: WICK
Pharma, Zweigniederlassung der Procter &
Gamble GmbH, 65823 Schwalbach,
Germany.
Manufacturer: Procter & Gamble
Manufacturing GmbH,

製品の特徴

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Vicks Inhaler Nasal Stick
Menthol 125mg
Camphor 50mg
Siberian Pine Needle Oil 10mg
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENTS
mg/inhaler
Menthol
125.00
Camphor
50.00
Siberian Pine Needle Oil
10.00
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Nasal Stick
The nasal stick contains a cellulose wick soaked in 0.5ml of product.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
In the relief of symptoms of nasal congestion such as are associated
with allergic and
infectious upper respiratory tract disorders.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
_Adults and children over 6 years_
:
Vicks Inhaler is used by inserting the inhaler into
each nostril, holding the other nostril closed and
inhaling deeply.
It can be used as frequently as needed.
_ _
_Children under 6 years_
:
Not recommended
4.3 CONTRAINDICATIONS
Use in patients hypersensitive to any of the ingredients
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
If there is no improvement or aggravation of the disorder consult the
doctor.
4.5 INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None known
4.6 FERTILITY, PREGNANCY AND LACTATION
There is no evidence to indicate that this product should not be used
during pregnancy
and lactation.
4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
None
4.8 UNDESIRABLE EFFECTS
In general no serious or severe side effects are expected with this
product.
Very rarely cases of nasal discomfort have been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the
medicinal product is
important. It allows continued monitoring of the benefit/risk balance
of the medicinal
product. Healthcare professionals are asked to report any suspected
adverse reactions via
HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1
6764971; Fax:
[phone]. Website: www.hpra.ie; E-mail: [e-mail].
4.9 OVERDOSE
No clinically significant cases o